IN2014MN01551A - - Google Patents

Info

Publication number
IN2014MN01551A
IN2014MN01551A IN1551MUN2014A IN2014MN01551A IN 2014MN01551 A IN2014MN01551 A IN 2014MN01551A IN 1551MUN2014 A IN1551MUN2014 A IN 1551MUN2014A IN 2014MN01551 A IN2014MN01551 A IN 2014MN01551A
Authority
IN
India
Prior art keywords
geranylgeranylacetone
composition
cells
mixture
various retina
Prior art date
Application number
Inventor
MIYANOTakayuki
KUROSETakahiro
KATOMariyo
Yoshihiro Takai
Original Assignee
Rohto Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rohto Pharma filed Critical Rohto Pharma
Publication of IN2014MN01551A publication Critical patent/IN2014MN01551A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/121—Ketones acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions

Abstract

An ophthalmic composition containing a geranylgeranylacetone selected from (a) (b) or (c) mentioned below protects various retina cells from degeneration disorder or annihilation and significantly promotes the survival of said cells. Therefore said composition exerts a dramatic effect in the prevention amelioration or treatment of various retina disorders. Moreover the composition is less likely to become cloudy when being stored. (a) A mixture of 5E 9E 13E geranylgeranylacetone and 5Z 9E 13E geranylgeranylacetone the mixture containing 80 weight% or more of the 5E 9E 13E geranylgeranylacetone; (b) only 5E 9E 13E geranylgeranylacetone; (c) only 5Z 9E 13E geranylgeranylacetone.
IN1551MUN2014 2012-02-27 2013-02-25 IN2014MN01551A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012040779 2012-02-27
PCT/JP2013/054779 WO2013129317A1 (en) 2012-02-27 2013-02-25 Ophthalmic composition containing geranylgeranylacetone

Publications (1)

Publication Number Publication Date
IN2014MN01551A true IN2014MN01551A (en) 2015-05-08

Family

ID=49082514

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1551MUN2014 IN2014MN01551A (en) 2012-02-27 2013-02-25

Country Status (7)

Country Link
US (2) US20130303624A1 (en)
JP (2) JP5358748B1 (en)
CN (1) CN104136018A (en)
HK (1) HK1200112A1 (en)
IN (1) IN2014MN01551A (en)
TW (1) TWI564006B (en)
WO (1) WO2013129317A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI564006B (en) * 2012-02-27 2017-01-01 樂敦製藥股份有限公司 Ophthalmic composition comprising geranylgeranylacetone
JP5483513B1 (en) * 2013-02-19 2014-05-07 ロート製薬株式会社 Mucosal application agent for prevention, improvement, or treatment of retinal diseases
JP5687395B2 (en) * 2013-02-19 2015-03-18 ロート製薬株式会社 Mucosal application agent for prevention, improvement, or treatment of retinal diseases
WO2015029925A1 (en) * 2013-08-26 2015-03-05 ロート製薬株式会社 Prophylactic, ameliorative, or therapeutic agent for retinopathy
CN110893180A (en) * 2018-09-12 2020-03-20 厦门信力康生物技术有限公司 Application of teprenone and derivatives thereof in preparing drugs for treating drug addiction and preventing relapse

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06192073A (en) * 1992-12-24 1994-07-12 Eisai Co Ltd Cell differentiation-inducing agent
JPH08133967A (en) * 1994-11-02 1996-05-28 Eisai Co Ltd Agent for treating dry eye
JP2000319170A (en) * 1999-03-05 2000-11-21 Eisai Co Ltd Teprenone-containing eye lotion
US20050009772A1 (en) * 2003-05-06 2005-01-13 The Regents Of The University Of California Methods and compositions for the treatment of glaucoma and other retinal diseases
JP5027425B2 (en) * 2006-02-17 2012-09-19 エーザイ・アール・アンド・ディー・マネジメント株式会社 Channel disease therapeutic agent containing geranylgeranylacetone as an active ingredient
CN1903188B (en) * 2006-08-03 2011-07-27 首都医科大学附属北京同仁医院 Application of teprenone for preparing medicine for treating and/or preventing glaucoma
CA2806238A1 (en) * 2010-09-01 2012-03-08 Coyote Pharmaceuticals, Inc. Methods for treating neurodegenerative diseases
CN102627539B (en) * 2011-10-19 2014-04-16 利安隆博华（天津）医药化学有限公司 Method for producing all trans-teprenone
TWI564006B (en) * 2012-02-27 2017-01-01 樂敦製藥股份有限公司 Ophthalmic composition comprising geranylgeranylacetone

Also Published As

Publication number Publication date
JPWO2013129317A1 (en) 2015-07-30
JP5358748B1 (en) 2013-12-04
CN104136018A (en) 2014-11-05
HK1200112A1 (en) 2015-07-31
US20140350119A1 (en) 2014-11-27
WO2013129317A1 (en) 2013-09-06
JP2013213050A (en) 2013-10-17
TWI564006B (en) 2017-01-01
TW201340963A (en) 2013-10-16
US20130303624A1 (en) 2013-11-14

Similar Documents

Publication Publication Date Title
CA2900335C (en) Synthetic analogs of epipolythiodioxopiperazines and uses thereof
PE20150223A1 (en) ANTIBODIES ENHANCED ANTIBODIES AGAINST GROWTH AND DIFFERENTIATION FACTOR-8 AND THE USES OF THEM
PH12015500115B1 (en) Glucagon analogues
CA2840307C (en) Progenitor cells of mesodermal lineage
IN2014MN01551A (en)
MX2013004061A (en) Cyclosporin analogs.
SG10201809290SA (en) Compositions and Methods to Treating Hemoglobinopathies
IN2014DN10386A (en)
MX365160B (en) Novel compounds as modulators of protein kinases.
IL234101B (en) Compositions comprising acamprosate and baclofen for use in the treatment of parkinsonism
IN2014MN01552A (en)
IN2014MN01553A (en)
IN2014DN07326A (en)
MX362854B (en) Sirna and their use in methods and compositions for the treatment and/or prevention of eye conditions.
NZ713129A (en) Oxprenolol compositions for treating cancer
MX355668B (en) Use of a myrtle extract as an anti-biofilm agent against p. acnes.
MX354727B (en) Composition for use in the promotion of magnesium absorption and/or magnesium retention.
WO2015024577A3 (en) Safranal-based composition
MX2017004649A (en) Nanostructured formulations for the delivery of silibinin and other active ingredients for treating ocular diseases.
GB201114230D0 (en) Addition copolymers and their use
MX356052B (en) Synergistic therapies of cannabidiol with hypothermia for neuroprotection.
CA2836488C (en) Methods for treating obesity and/or metabolic syndrome
PH12015501109A1 (en) Novel compounds as diacylglycerol acyltransferase inhibitors
UA79527U (en) remineralization gel with hydroxyapatite
MY183421A (en) Medical device for controlled release of drug